We performed a multistage genome-wide association study including 7,683 individuals with pancreatic cancer and 14,397 controls of European descent. Four new loci reached genomewide significance: rs6971499 at 7q32.3 (LINC-PINT, per-allele odds ratio (OR) = 0.79, 95% confidence interval (CI) 0.74-0.84, P = 3.0 × 10 −12 ), rs7190458 at 16q23.1 (BCAR1/CTRB1/CTRB2, OR = 1.46, 95% CI 1.30-1.65, P = 1.1 × 10 −10 ), rs9581943 at 13q12.2 (PDX1, OR = 1.15, 95% CI 1.10-1.20, P = 2.4 × 10 −9 ) and rs16986825 at 22q12.1 (ZNRF3, OR = 1.18, 95% CI 1.12-1.25, P = 1.2 × 10 −8 ). We identified an independent signal in exon 2 of TERT at the established region 5p15.33 (rs2736098, OR = 0.80, 95% CI 0.76-0.85, P = 9.8 × 10 −14 ). We also identified a locus at 8q24.21 (rs1561927, P = 1.3 × 10 −7 ) that approached genome-wide significance located 455 kb telomeric of PVT1. Our study identified multiple new susceptibility alleles for pancreatic cancer that are worthy of follow-up studies.
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Pancreatic cancer is the fourth-leading cause of cancer-related death in the United States and the fifth-leading cause in the European Union 1,2 . Over 80% of patients have incurable disease at the time of diagnosis, and the majority live for less than 12 months 3 . Rare, moderately to highly penetrant mutations account for a small fraction of the familial aggregation of pancreatic cancer 4 . In two previous genome-wide association studies (GWAS) called PanScan I 5 and PanScan II 6 , we identified common variants at four loci that are associated with risk of sporadic pancreatic cancer in European populations. Subsequent GWAS demonstrated five distinct susceptibility loci among individuals of Chinese descent 7 and three suggestive loci among individuals of Japanese descent 8 .
In the current study (designated PanScan III), we performed a multistage GWAS of 7,683 individuals diagnosed with pancreatic cancer and 14,397 control individuals of European descent (Online Methods, Table 1, Supplementary Table 1 and Supplementary Fig. 1 ).
Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer
In stage 1, we newly genotyped 1,582 cases from 13 prospective cohort studies, 2 case series and 1 case-control study using the Illumina OmniExpress Beadchip array. The control population included 5, 203 cancer-free individuals that were genotyped previously using secondgeneration Illumina SNP microarrays (for example, OmniExpress, Omni 1M or Omni 2.5M) and were drawn from PanScan III prospective cohorts and a Spanish case-control study of bladder cancer. Of the newly genotyped cases, 94% passed quality-control criteria (Online  Methods and Supplementary Tables 2 and 3) , and 712,704 SNPs were included with a minimum call rate of 94%. In stage 2, we used the primary whole genome-scan data from the reported PanScan I 5 (1,757 cases and 1,801 controls from 12 cohort studies and 1 case-control study typed on the Illumina HumanHap550 array) and PanScan II 6 (1,768 cases and 1,841 controls from 8 case-control studies typed with the Illumina Human 610-Quad array) studies. To address differences in typed SNPs across the arrays, we used the Division of Cancer Epidemiology and Genetics (DCEG) Imputation Reference Set 9 to fill in missing genotypes (Online Methods).
In a meta-analysis of stages 1 and 2, we observed robust associations for the four previously identified loci in individuals of European descent: rs687289 at 9q34.2 (ABO, OR = 1.27, 95% CI 1.20-1.35, P = 1.6 × 10 −16 ), rs9543325 at 13q22.1 (KLF5/KLF12, OR = 1.23, 95% CI 1.18-1.30, P = 4.3 × 10 −14 ), rs10919791 at 1q32.1 (NR5A2, OR = 0.79, 95% CI 0.75-0.85, P = 1.4 × 10 −11 ) and rs31490 at 5p15.33 (CLPTM1L, OR = 1.20, 95% CI 1.14-1.27, P = 2.0 × 10 −11 ).
We observed two new SNPs below genome-wide significance (P < 5 × 10 −8 ) in the meta-analysis of stages 1 and 2, plus 11 additional promising SNPs (P < 5 × 10 −5 ) from distinct regions (Supplementary Table 4 ). We carried these 13 SNPs forward for replication (stage 3) in 2,576 cases and 5,552 controls, drawn from (i) cases in stage 1 with DNA quantity insufficient for the full GWAS, (ii) cases and controls Table 5 ). We selected additional control subjects from cancer-free individuals genotyped previously using the Illumina HumanHap550 array (Online Methods). Of the 13 SNPs advanced to replication, 9 were associated with pancreatic cancer risk (P < 0.05) in the replication stage (Supplementary Table 6 ).
For the complete study of 7,683 cases and 14,397 controls, we applied a fixed-effect meta-analysis to the results from the three stages. Overall, six SNPs had P values below genome-wide significance: rs2736098 at 5p15.33 (a second signal in TERT, P = 9.8 × 10 −14 ), rs6971499 at 7q32.3 (LINC-PINT, P = 3.0 × 10 −12 ), rs7190458 at 16q23.1 (BCAR1/CTRB1/CTRB2, P = 1.1 × 10 −10 ), rs9581943 at 13q12.2 (PDX1, P = 2.4 × 10 −9 ), rs16986825 at 22q12.1 (ZNRF3, P = 1.2 × 10 −8 ) ( Table 2 and Fig. 1 ) and rs4962153 at 9q34.2 (ADAMTS13, P = 1.5 × 10 −8 ). In a subsequent conditional analysis described below, rs4962153 in ADAMTS13 marked the same signal as rs687289 in ABO identified in PanScan I and II. An additional locus at 8q24.21 was close to genome-wide significance (rs1561927, P = 1.3 × 10 −7 ) and is located in a region that has been associated previously with multiple cancers ( Table 2 and Fig. 1 ).
The SNP at 7q32.3, rs6971499, maps to an intron in LINC-PINT, which is a p53-induced long intergenic non-protein coding RNA located in a 375-kb region between MKLN1 (encoding muskelin 1) and KLF14 (Supplementary Table 7 and Fig. 1 ). Muskelin 1 is an intracellular protein that mediates cell responses to the extracellular matrix, in particular influencing cell adhesion and cytoskeleton organization 12 . KLF14 is a member of the Kruppel-like family of transcription factors, which have been implicated as tumor suppressors, including in mutant KRAS-driven tumors 13 . KLF14 has also been identified as a regulator of several metabolic phenotypes, including type 2 diabetes 14 . Notably, the previously established susceptibility locus at 13q22.1 is located in an intergenic region between KLF5 and KLF12, which encode two other members of the Kruppel-like family of transcription factors.
The SNP at 16q23.1, rs7190458, is a synonymous SNP residing in the last exon of BCAR1 (also known as P130Cas) and close to two chymotrypsinogen genes, CTRB1 (5 kb) and CTRB2 (23 kb) (Supplementary Table 7 and Fig. 1 ). Aberrant expression of BCAR1 has been linked with the transformation and progression of multiple cancer types, and BCAR1 functions as an adaptor protein that coordinates cell cycle control, cytoskeleton organization and cell migration 15, 16 . Table 7 and Fig. 1) . PDX1 is critical for early pancreatic development, has a role in differentiation of the exocrine pancreas and regulates beta-cell function in the mature pancreas 24, 25 . Mutations in PDX1 have been linked to agenesis of the pancreas 24 and maturity onset diabetes of the young 26 , a dominantly inherited disorder of nonautoimmune diabetes. Furthermore, PDX1 has been implicated in glucose-dependent regulation of insulin gene transcription 27 , and GWAS have identified a SNP (rs2293941, r 2 = 0.20 in the 1000G CEU data) at the PDX1 locus that is associated with fasting glucose levels 28 .
The signal at 22q12.1, rs16986825, maps to an intron in ZNRF3 (zinc and ring finger 3) (Supplementary Table 7 and Fig. 1) , encoding a cell-surface transmembrane E3 ubiquitin protein ligase that is a negative regulator of the Wnt signaling pathway 29 . Additionally, CHEK2 is located 162 kb centromeric to the marker SNP and encodes a cell cycle-checkpoint kinase that cooperates with P53, BRCA1 and ATM in response to DNA damage 30 . Alterations in CHEK2 have been implicated in susceptibility to several cancer types 31 .
We performed conditional analyses to assess whether the newly identified SNPs at 5p15.33 (CLPTM1L and TERT) and 9q34.2 (ABO and ADAMTS13) were independent from those identified previously. After conditioning on the reported SNP within intron 13 of CLPTM1L, the newly identified synonymous SNP within the second exon of TERT (rs2736098) remained statistically significant (P = 2.4 × 10 −3 ) ( Table 3) . Two strong recombination hotspots lie between the established and new SNPs in the 1000G CEU data (likelihood ratios of 27.1 and 261.0) 32 , and the two SNPs are in modest linkage disequilibrium (LD; r 2 = 0.22 in the 1000G CEU data) (Fig. 1) .
TERT encodes the catalytic subunit of telomerase reverse transcriptase, a component of the ribonucleoprotein complex that maintains the integrity of chromosome ends. Inherited mutations affecting TERT underlie cases of dyskeratosis congenita, aplastic anemia, acute myeloid leukemia, familial melanoma and pulmonary fibrosis 33, 34 . CLPTM1L encodes the cleft lip and palate associated transmembrane 1-like protein that is involved in mediating apoptosis, aneuploidy, cisplatin resistance and RAS-mediated malignant transformation 35, 36 . Variants across the TERT and CLPTM1L region have been associated previously with risk of multiple cancers. Furthermore, independent signals within TERT and CLPTM1L have been identified for bladder cancer 37 , chronic lymphocytic leukemia 38 and lung cancer 37, 39 , and fine-mapping studies have identified at least four independent signals across the TERT and CLPTM1L region that are associated with cancer 40, 41 . The new SNP identified in PanScan III (rs2736098) is located in a region of LD spanning ~4 kb from the promoter region to exon 2 of TERT. This SNP and several correlated SNPs have been associated with telomere length in white blood cells, as well as TERT promoter activity 37, 40, 41 . The minor allele of rs2736098 that is associated with npg l e t t e r s a lower risk of pancreatic cancer in PanScan is also associated with longer telomeres and lower risk of breast cancer 40 . Although further characterization of this region will be necessary, the new SNP in exon 2 of TERT appears to mark an independent risk locus for pancreatic cancer.
After conditioning on the established SNP at 9q34.2 in the first intron of ABO, the SNP rs4962153 in ADAMTS13 identified in PanScan III was not statistically significant (P = 0.28), indicating that these two SNPs point to the same susceptibility haplotype ( Table 3) .
We identified a promising risk locus at 8q24.21 (rs1561927, P = 1.3 × 10 −7 ) in a nongenic region between PVT1 and LINC00977 (Supplementary Table 7 and Fig. 1 ). 8q24.21 is known to contain multiple cancer susceptibility loci that span over 2 Mb 42, 43 . The promising pancreatic cancer SNP is in LD with a SNP that is associated with ovarian cancer risk (rs10088218, r 2 = 0.37 in the 1000G CEU data, 24 kb upstream) 44 , and the closest genes are centromeric to rs1561927: MIR1208 (406 kb), PVT1 (455 kb) and MYC (814 kb). Several 8q24.21 risk loci have been shown to interact with MYC or PVT1 promoters through long-range chromosomal interaction, and allele-specific effects on the expression of both genes have been reported 42, 45, 46 . However, these loci are located more than 1 Mb upstream of rs1561927 on 8q24.21 (r 2 < 0.03 in the 1000G CEU data).
In stratified analyses, we noted no statistically significant heterogeneity by geographic region or smoking status ( Supplementary  Tables 8 and 9) . In a preliminary analysis that included 173 cases and 430 controls of Asian ancestry (Supplementary Table 10) , we examined the susceptibility loci identified in individuals of European descent 5, 6 ( Table 2) . We also assessed previously published pancreatic cancer risk loci from individuals of Chinese 7 and Japanese 8 ancestry, noting no loci and one locus, respectively, as being nominally statistically significant in PanScan (Supplementary Table 11) .
To pursue the first steps toward understanding the functional underpinnings of the newly identified risk alleles, we conducted bioinformatic analyses using HaploReg 47 (Supplementary Table 12) . We also evaluated expression quantitative trait locus (eQTL) effects [48] [49] [50] (Supplementary Table 12 ). We noted cis-eQTLs on chromosome 16q23.1 in peripheral blood (CFDP1), chromosome 13q12.2 in skin and liver (POMP), chromosome 22q12.1 in liver and peripheral blood (CCDC117) and peripheral blood (XBP1) and chromosome 8q24.21 in adipose tissue (PVT1). XBP1 at chromosome 22q12.1 regulates pancreatic beta-cell function with effects on systemic glucose control 51 and modulates acinar cell homeostasis 25 . In a gene set enrichment analysis 52 of genes within 100 kb of the ten index SNPs identified in PanScan, the only statistically significant pathway was maturity onset diabetes of the young (P = 3.3 × 10 −4 ). Understanding the functional consequences of pancreatic cancer susceptibility variants will require further laboratory investigation.
In a linear-mixed model analysis 53 (Online Methods), we estimated that the heritability for pancreatic cancer due to common SNPs present on GWAS arrays was 13% (95% CI 4-22%). Furthermore, we estimated that the nine loci identified in individuals of European ancestry account for approximately 9% of the total heritability tagged by common SNPs. We also evaluated the cumulative association with pancreatic cancer of risk alleles at susceptibility loci identified in individuals of European descent. Compared to individuals with the most prevalent number of risk alleles in controls (n = 10), those with ≤6 risk alleles had an OR of 0.55 (95% CI 0.44-0.68) and those with ≥14 risk alleles had an OR of 2.24 (95% CI 1.80-2.80) for pancreatic cancer (Supplementary Fig. 2 ).
In conclusion, our multistage GWAS revealed new loci that are associated with pancreatic cancer risk, as well as promising loci that merit follow-up study. Several of the new loci harbor plausible candidate genes that have been implicated in pancreas development, pancreatic beta-cell function and predisposition to diabetes. Further investigation is warranted to understand the biological underpinnings of these common pancreatic cancer susceptibility alleles.
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Methods and any associated references are available in the online version of the paper. Table 6 ). This was followed by a meta-analysis of stages 1 and 2 and the replication for the 13 SNPs using the same fixed-effects inversevariance method.
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Technical validation.
A comparison of the genotyping calls from the imputation of PanScan I and II into the OmniExpress array contents and confirmatory TaqMan assays (n = 511 samples from PanScan I and II) yielded r 2 values of 0.74, 0.96, 0.56, 0.99, 0.98 and 1.00 for rs2736098, rs6971499, rs7190458, rs9581943, rs16986825 and rs1561927, respectively.
Estimate of recombination hotspots. To identify recombination hotspots, we used SequenceLDhot 32 , a program that uses the approximate marginal likelihood method 71 and calculates likelihood ratio statistics at a set of possible hotspots. We tested five unique sets of 100 control samples. The PHASE v2.1 program was used to calculate background recombination rates 72, 73 , and LD heat maps were visualized using the snp.plotter program 74 . For an estimation of recombination hotspots between loci in TERT and CLPTM1L on chromosome 5p15.33, we used the 1000G (version 3) CEU data.
Heritability analysis. To estimate the heritability explained by common SNPs present on GWAS arrays on the liability scale (lifetime disease risk of 0.015), we used GCTA 53,75 on a set of LD-pruned SNPs (r 2 < 0.5) that passed the following stringent quality-control thresholds: MAF > 1%, SNP missing rates <5%, subject missing rate <1% and Hardy-Weinberg equilibrium P values >10 −4 . Nonautosomal SNPs and pairs of subjects with genetic relatedness >5% were removed. These analyses were run separately in PanScan I, II and III adjusting for age, sex, study (or geographic region in PanScan III) and the significant principal components in each study. PanScan III analyses were restricted to participating studies that contributed both cases and controls. PanScan I, II and III results were combined in a meta-analysis. We repeated the analyses restricted to the genome wide-significant SNPs in individuals of European ancestry to estimate the proportion of heritability tagged by these nine SNPs.
Further follow-up analyses. We constructed a genetic risk score for pancreatic cancer incorporating the susceptibility loci identified in PanScan I, II and III. For this analysis, subjects could possess 0-20 risk alleles based on their genotypes at the 10 identified loci. ORs were calculated using multivariableadjusted unconditional logistic regression with meta-analysis to combine data from stages 1 and 2, as was done in the analyses of individual SNPs. Replication samples were not genotyped for the four susceptibility loci identified in PanScan I and II, and therefore these subjects could not be included in the risk score analysis. Subjects with missing genotypes for one or more of the ten SNPs (n = 898) were assigned the most common genotype at that SNP among cases or controls. In sensitivity analyses, results were unchanged if these subjects were excluded. Using 1000G CEU data, we identified SNPs with r 2 > 0.7 with our lead SNP. We used HaploReg v2 (ref. 47 ), a tool for exploring noncoding functional annotation using ENCODE data, to evaluate the genome surrounding our SNPs (Supplementary Table 12 ). In addition, we evaluated cis associations between all new and promising SNPs discovered in this study and the expression of nearby genes in skin biopsies, adipose biopsies and nontransformed peripheral blood samples from subjects of European descent from publically available data sets 48, 50 (Supplementary Table 12) . Gene set enrichment analysis was also performed for genes in pancreatic cancer risk loci identified in subjects of European descent (in a window of 100 kb centered on the most significant SNP in each locus) based on KEGG (Kyoto Encyclopedia of Genes and Genomes) annotations using GeneCodis3 with reporting of the corrected hypergeometric P value 52 .
